Organization | AvroBio

AvroBio Report issue

For profit Phase 2

Founded: Cambridge MA United States (2015)

Organization Overview

First Clinical Trial

2018

NCT03454893

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

AvroBio

Active Ingredients

Drugs in Phase 2 Trials (2)

autologous cd34+ cell-enriched fraction that contains cells transduced with lentiviral vector/alpha-galactosidase a (1 trial)

avr-rd-02 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Fabry Disease (Phase 2)

Gaucher Disease (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial APIs: 2